LUND, Sweden, Jan. 19, 2021 /PRNewswire/ -- Immunovia AB,
("Immunovia") announces today that Patrik Dahlen, CEO of Immunovia, has purchased
250,000 warrants of the 2020/2024 scheme for approximately 400
KSEK. His total holding now amounts to 45,000 shares and 250,000
warrants in Immunovia. The warrants have a subscription price per
share of SEK 455. Other management
team members have subscribed for 4,000 warrants of the same
scheme.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Patrik Dahlen, CEO, Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/chief-executive-officer--patrik-dahlen-buys-immunovia-warrants,c3270453
The following files are available for download:
|
https://mb.cision.com/Main/13121/3270453/1360939.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/chief-executive-officer-patrik-dahlen-buys-immunovia-warrants-301210895.html
SOURCE Immunovia AB